Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET. A live and archived webcast will be available via the company Investor Events and Presentations page.
Details
News Market Reaction – UNCY
On Apr 9, the day this news came out, UNCY closed 3.10% above the previous close.
Data tracked by StockTitan Argus for the Apr 9 session.
Key Figures
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
- Presentation date
- April 15, 2026
- Needham Virtual Healthcare Conference
- Presentation time
- 3:45 p.m. ET
- Needham Virtual Healthcare Conference
Historical Context
-
Full-year 2025 results, NDA resubmission acceptance, cash runway into 2027.
-
CEO fireside chat at Guggenheim biotech summit with webcast access.
-
FDA acceptance of OLC NDA resubmission with June 27, 2026 PDUFA date.
-
Resubmission of OLC NDA, expecting new 1H 2026 PDUFA date guidance.
-
Participation in December 2025 investor conferences with webcast availability.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.